- Home
- XFOR vs NBP Comparison
XFOR vs NBP Comparison
Compare XFOR & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | NBP |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | 143 | 32 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 379.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XFOR | NBP |
|---|---|---|
| Price | $4.39 | $3.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $25.20 | $9.00 |
| AVG Volume (30 Days) | 583.2K | ★ 602.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,263.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $3.03 |
| 52 Week High | $6.63 | $5.19 |
Technical Indicators
Market Signals| Indicator | XFOR | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 48.07 |
| Support Level | $3.38 | $3.04 |
| Resistance Level | $4.53 | $3.74 |
| Average True Range (ATR) | 0.24 | 0.28 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 72.49 | 40.96 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.